Blood Test Predicts Onset of Alzheimer's Disease
|
By LabMedica International staff writers Posted on 22 Jul 2014 |

Image: The Luminex 200 System for Multiplex Testing (Photo courtesy of the University of Utah).
A combination of 10 proteins could predict whether individuals would progress from mild cognitive impairment to Alzheimer's disease (AD) within a year has been discovered.
Mild cognitive impairment (MCI) which includes problems with day-to-day memory, attention and language can be an early sign of dementia, but it can also be a symptom of stress or anxiety. About 10% of people with MCI go on to develop dementia within a year, however, apart from regular memory tests, there is currently no reliable way to predict who will and will not be among them.
Scientists at King's College London (UK) working with Proteome Sciences plc (Cobham, UK) analyzed blood samples from 1,148 subjects: 476 with AD, 220 with MCI, and 452 elderly controls with no dementia. The team analyzed 26 proteins in the blood samples and found that 16 linked strongly to brain shrinkage in the MCI and Alzheimer's groups. All candidate proteins were measured using xMAP multiplex bead assays incorporated in 7 MILLIPLEX MAP panels run on the Luminex 200 instrument (Luminex; Austin, TX, USA).
In a secondary analysis they discovered that a combination of 10 proteins could predict whether individuals would progress from MCI to Alzheimer's disease within a year with an accuracy of 87%. They found that the proteins transthyretin (TTR), clusterin, cystatin C, alpha-1-acid glycoprotein (A1AcidG), Intercellular Adhesion Molecule 1 (ICAM1), cytochrome c4 precursor (CC4), pigment epithelium-derived factor (PEDF), alpha 1-antitrypsin (A1AT), Chemokine ligand 5 (RANTES), and Apolipoprotein C-III (ApoC3) plus the Apolipoprotein E (APOE) genotype, had the greatest predictive power.
Abdul Hye, PhD, the lead author of the study said, “The study marks the end of many years' work to find which of the thousands of proteins in the blood were clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment will develop Alzheimer's disease within a year, with a high level of accuracy.” The study was published on July 10, 2014, in the journal Alzheimer's and Dementia.
Related Links:
King's College London
Proteome Sciences plc
Luminex
Mild cognitive impairment (MCI) which includes problems with day-to-day memory, attention and language can be an early sign of dementia, but it can also be a symptom of stress or anxiety. About 10% of people with MCI go on to develop dementia within a year, however, apart from regular memory tests, there is currently no reliable way to predict who will and will not be among them.
Scientists at King's College London (UK) working with Proteome Sciences plc (Cobham, UK) analyzed blood samples from 1,148 subjects: 476 with AD, 220 with MCI, and 452 elderly controls with no dementia. The team analyzed 26 proteins in the blood samples and found that 16 linked strongly to brain shrinkage in the MCI and Alzheimer's groups. All candidate proteins were measured using xMAP multiplex bead assays incorporated in 7 MILLIPLEX MAP panels run on the Luminex 200 instrument (Luminex; Austin, TX, USA).
In a secondary analysis they discovered that a combination of 10 proteins could predict whether individuals would progress from MCI to Alzheimer's disease within a year with an accuracy of 87%. They found that the proteins transthyretin (TTR), clusterin, cystatin C, alpha-1-acid glycoprotein (A1AcidG), Intercellular Adhesion Molecule 1 (ICAM1), cytochrome c4 precursor (CC4), pigment epithelium-derived factor (PEDF), alpha 1-antitrypsin (A1AT), Chemokine ligand 5 (RANTES), and Apolipoprotein C-III (ApoC3) plus the Apolipoprotein E (APOE) genotype, had the greatest predictive power.
Abdul Hye, PhD, the lead author of the study said, “The study marks the end of many years' work to find which of the thousands of proteins in the blood were clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment will develop Alzheimer's disease within a year, with a high level of accuracy.” The study was published on July 10, 2014, in the journal Alzheimer's and Dementia.
Related Links:
King's College London
Proteome Sciences plc
Luminex
Latest Clinical Chem. News
- Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
- Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
- FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
- Skin Swab Research Identifies Metabolic Changes Linked to Parkinson’s Disease
- AI Predicts Kidney Stone Composition From Routine Urine Tests
- Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
- Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
- Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease
- New Biomarker Offers Longer Detection Window for Suspected GHB Exposure
- Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction
- Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
- Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
- Combined Blood and Imaging Data Help Identify More Lung Cancer Cases
- Blood Protein Panel Detects ALS with High Accuracy
- Single-Vesicle Analysis Reveals Tissue-Associated Inflammatory Signatures
- Plasma Proteomic Test Detects Immunotherapy Resistance Before Imaging in Lung Cancer
Channels
Molecular Diagnostics
view channel
Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







.jpg)